Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 417-060-2 | CAS number: 151006-61-0 1-DODECENE DIMER, HYDROGENATED; ALKANE 2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: inhalation
Administrative data
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- between 23 January 1995 and 6 March 1995
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted in compliance with agreed protocols, with no/or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 995
- Report date:
- 1995
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.1150 (Acute inhalation toxicity)
- Deviations:
- not applicable
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Date of inspection: 31st January 1994 Date of Signature:16th March 1994
- Test type:
- other:
- Limit test:
- yes
Test material
- Reference substance name:
- A mixture of isomers of branched tetracosane
- EC Number:
- 417-060-2
- EC Name:
- A mixture of isomers of branched tetracosane
- Cas Number:
- 151006-61-0
- Molecular formula:
- C24 H50
- IUPAC Name:
- A mixture of isomers of branched tetracosane
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River (UK) Ltd., Margate, Kent.
- Age at study initiation: ten to twelve weeks old
- Weight at study initiation:
Males 285g to 294g.
Females 214g - 251g.
- Fasting period before study: Not applicable
- Housing: polypropylene grid-floor cages over trays lined with absorbant paper.
- Diet: ad libitum (Rat and Mouse Expanded Pelleted Diet No. 1, Special Diets Services Limited, Witham, Essex, UK)
- Water: ad libitum (Mains drinking water)
- Acclimation period: at least seven days
ENVIRONMENTAL CONDITIONS
- Temperature: 19 to 23 deg C
- Humidity: 45 to 56%
- Air changes (per hr): Approximately 15 changes per hour.
- Photoperiod (hrs dark / hrs light): twelve hours continuous light and twelve hours darkness
IN-LIFE DATES: From: Day 1 To: Day 14
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- other: unchanged (no vehicle)
- Details on inhalation exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus:
A glass concentric jet nebuliser (Radleys, Saffron Walden, Essex, UK) located at the top of the exposure chamber/ The nebuliser was connected to a glass syringe attached to a modified infusion pump, which provided a continuous supply of test material under pressure, and to a metered compressed air supply.
- Exposure chamber volume:
approximately 30 litres
- Method of holding animals in test chamber:
Each rat was individually held in a tapered, polycarbonate restraining tube fitted onto a single tier of the exposure chamber and sealed by means of a rubber ‘O’ ring. Only the nose of each animal was exposed to the test atmosphere.
- Source and rate of air:
Compressed air was supplied by means of an oil free compressor and passed through a water trap and respiratory quality filters to removed particulate material above 0.005 microM before it was introduced to the glass concentric jet nebuliser. Chamber air flow rates were maintained at 16 l/m during each concentration, providing 32 air changes per hour.
- Method of conditioning air:
water trap and respiratory quality filters
- System of generating particulates:
A glass concentric jet nebuliser
- Method of particle size determination:
Marple Personal Cascade Impactor. This device consisted of six impactor stages with stainless steel collection substrates (10, 6, 3.5, 1.6, 0.9 and 0.5 micro/M cut off points) and a back up glass fibre filter housed in an aluminium sampler.
- Treatment of exhaust air:
filtered
- Temperature, humidity, pressure in air chamber:
Temperature and relative humidity inside the exposure chamber were measured by an electronic thermometer/humidity meter (Kane-May Ltd., Welwyn Garden City, Hertfordshire, UK) located in a vacant port in the animals’ breathing zone of the chamber and recorded every thirty minutes throughout the four-hour exposure period. The pressure in the air chamber was kept at negative pressure throughout the study.
TEST ATMOSPHERE
- Brief description of analytical method used:
Glass fibre filters (Gelman type A/E 25 mm) placed in a filter holder. The holder was temporarily sealed in a vacant port in the exposure chamber in the animals’ breathing zone and a suitable known volume of exposure chamber air was drawn through the filter using a vacuum pump (Gravimetric). Each filter was weighed before and after sampling in order to calculate the weight of collected test material.
- Samples taken from breathing zone:
yes
VEHICLE
- Composition of vehicle (if applicable): Not applicable
- Concentration of test material in vehicle: Not applicable
- Justification of choice of vehicle: Not applicable
- Lot/batch no. (if required): Not applicable
- Purity: Not applicable
TEST ATMOSPHERE (if not tabulated)
- Particle size distribution:
Determined three or four times during each exposure period.
Please see Table 2 for a summary of the results
- MMAD (Mass median aerodynamic diameter):
Group 1 - 1.7
Group 2 - 1.8
Group 3 - 1.7
CLASS METHOD (if applicable)
- Rationale for the selection of the starting concentration:
During the characterisation phase two animals (one male one female) were introduced to an atmosphere of the test material at a concentration of approximately 2.5 mg/l for 168 minutes as a preliminary screen. Since no adverse effects were noted and after consultation with the study sponser, the study was started at the limit test concentration (5 mg/l). - Analytical verification of test atmosphere concentrations:
- no
- Remarks:
- Gravimetric only
- Duration of exposure:
- 4 h
- Concentrations:
- Characterisation phase:
approximately 2.5 mg/l
Main study
Group 1 Males and Females:
Target concentration - 5 mg/l
Mean achieved - 5.06 mg/l
Nominal concentration - 19.1 mg/l
Group 2 Females
Target concentration - not recorded
Mean achieved - 2.57 mg/l
Nominal concentration - 9.9 mg/l
Group 3 Females
Target concentration - not recorded
Mean achieved - 1.19 mg/l
Nominal concentration - 4.5 mg/l - No. of animals per sex per dose:
- Characterisation phase:
1 male, 1 female
Main study
Group 1:
5 males and 5 females
Group 2:
5 females
Group 3:
5 females - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration:
14 days.
- Frequency of observations and weighing:
All animals were observed for clinical signs at hourly intervals during exposure, immediately on removal from the restraining tubes at the end of exposure, one hour after termination of exposure and subsequently once daily for fourteen days. Individual bodyweights were recorded prior to treatment on the day of exposure and on Days 7 and 14 or at death.
- Necropsy of survivors performed:
All animales, including those that died during the study, were subjected to a full external and internal examination, and any macroscopic abnormalities were recorded.
- Other examinations performed:
The respiratory tract was subjected to a detailed macroscopic examination for signs of irritatancy or local toxicity.
The lungs *, larynx, pharynx, trachea, kidneys, liver, nasal cavities and sinuses were retained from all animals together with tissues showing macroscopic abnormalities and preserved in buffered 10% formalin.
* Lungs were perfused with buffered 10% formalin. - Statistics:
- Data evaluations included the relationship, if any, between the animals’ exposure to the test material and the incidence and severity of all abnormalities including behavioural and clinical observations, necropsy findings, bodyweight changes, mortality and any other toxicological effects.
Using the mortality data obtained, an estimate of the acute inhalation median lethal concentration (LC50) of the test material was made.
Results and discussion
Effect levelsopen allclose all
- Sex:
- female
- Dose descriptor:
- LC50
- Effect level:
- 1.71 mg/L air
- Exp. duration:
- 4 h
- Sex:
- male
- Dose descriptor:
- LC50
- Effect level:
- > 5.06 mg/L air
- Exp. duration:
- 4 h
- Mortality:
- The mortality data is summarised in Table 1.
All animals that died during the study were found dead on day one following exposure. - Clinical signs:
- other: During exposure wet fur and increased respiratory rate were commonly noted. On removal from the chamber hunched posture, pilo-erection and incidents of ptosis were also noted in all dose groups and in the females exposed to 1.19 mg/l there were signs of l
- Body weight:
- Surviving animals showed normal bodyweight gain during the study.
- Gross pathology:
- At necropsy animals that died during the study commonly showed swollen and abnormally dark lungs and dark liver whilst several showed reddening of the small intestine. Dark kidneys were noted in one male exposed to 5.06 mg/l and pale kidney were noted in one of the females exposed to 2.57 mg/l. No abnormalities were detected in surviving animals at necropsy.
- Other findings:
- Not applicable.
Any other information on results incl. tables
Table 1 Mortality Data
Group number | Mean Achieved Atmosphere Concentration (mg/L) | Sex | Deaths During Exposure | Deaths Post Exposure (1 Hour) | Deaths During Day of Observation | Total Deaths | |||||||
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 - 14 | ||||||
1 | 5.04 | Male | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5/10 |
Female | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
2 | 2.57 | Female | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3/5 |
3 | 1.19 | Female | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2/5 |
Table 2 Summary of Particle Size Distribution
Group Number | Mean Achieved Atmosphere Concentration (mg/L) | Mean Mass Median Aerodynamic Diameter (microM) | Inspirable fraction (% <4 microM) | Geometric Standard Deviation (microM) |
1 | 5.04 | 1.7 | 82.0 | 0.40 |
2 | 2.57 | 1.8 | 85.2 | 0.46 |
3 | 1.19 | 1.7 | 86.2 | 0.45 |
Table 3 Individual Clinical Observations - Dose Group 1
Mean Achieved Atmospheric Concentration (mg/l) | Animal Number and sex | Effects Noted during Exposure (hour) | Effects noted Post Exposure (hour) | Effects Noted during day of observation | ||||||||||
1 | 2 | 3 | 4* | 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 - 14 | ||
5.06 | 1 MALE | Ri | Ri | Ri | WfRi HP | HPRi | HLP Ri | HPRi | H Ri | Ri | Ri | Ri | Ri | 0 |
2 MALE | 0 | 0 | Ri | WfRi HP | HPRiPt | HPRi | HPRi | HPRi | HPRi | HPRi | Ri | Ri | 0 | |
3 MALE | Ri | Ri | WfRi | WfRi HP | HPRi | x | ||||||||
4 MALE | 0 | Ri | Ri | WfRd PtHP | HPRdPt | HLP Rd | HPRd | HPRi | Ri | Ri | Ri | Ri | 0 | |
5 MALE | WfRi | WfRi | WfRi | WfRi PtHP | HPRiPt | HLP Ri | HPRi Ri | HPRi | HPRi | HPRi | Ri | Ri | 0 | |
6 FEMALE | 0 | Ri | Ri | WfHP Ri | HPRiPt | x | ||||||||
7 FEMALE | 0 | WfRi | WfRi | WfHP Ri | HPRiPt | x | ||||||||
8 FEMALE | 0 | WfRi | WfRi | WfHP Ri | HPRdPt | x | ||||||||
9 FEMALE | 0 | WfRi | WfRi | WfHP RiPt | HPRiPt | x | ||||||||
10 FEMALE | 0 | WfRi | WfRi | WfHP Ri | HPRiPt | HLP RiPt | HLP Ri | HPRi | HPRi | HPRi | HPRi | HPRi | HPRi* |
* = immediately after removal of animals from restraining tube
HPRi* = hunched posture day 8 only, pilo-erection and increased respiratory rate days 8 and 9 only.
Table 4 Individual Clinical Observations - Dose Group 2
Mean Achieved Atmospheric Concentration (mg/l) | Animal Number and sex | Effects Noted during Exposure (hour) | Effects noted Post Exposure (hour) | Effects Noted during day of observation | ||||||||||
1 | 2 | 3 | 4* | 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 - 14 | ||
2.57 | 11 FEMALE | 0 | Ri | Ri | WfHP Ri | HPRiPt | HPRi | HPRi | HPRi | HPRi | Hri | Ri | Ri | Ri* |
12 FEMALE | 0 | 0 | 0 | WfHP RiPt | HPRiPt | x | ||||||||
13 FEMALE | 0 | Ri | WfRi | WfHP Ri | WfHP RiPt | x | ||||||||
14 FEMALE | Wf | WfRi | WfRi | WfHP RiPt | HPRiPt | HPRi | HPRi | HPRi | HPRi | Ri | Ri | Ri | Ri* | |
15 FEMALE | WfRi | WfRi | WfRi | WfHP RiPt | HPRiPt | x |
* = immediately after removal of animals from restraining tube
Ri* = increased respiratory rate day 8 only.
Table 5 Individual Clinical Observations - Dose Group 3
Mean Achieved Atmospheric Concentration (mg/l) | Animal Number and sex | Effects Noted during Exposure (hour) | Effects noted Post Exposure (hour) | Effects Noted during day of observation | ||||||||||
1 | 2 | 3 | 4* | 1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 - 14 | ||
1.19 | 16 FEMALE | 0 | WfRi | WfRi | WfHPL RiPtE | WfHP RiWtPt | HPRi Pt | HPRi | H Ri | Ri | Ri | Ri | Ri | Ri* |
17 FEMALE | 0 | Ri | Ri | WfHP Ri | HPRi | HPRi | HPRi | HPRi | Ri | Ri | Ri | Ri | Ri* | |
18 FEMALE | 0 | Ri | Ri | WfHP Ri | HPRi | HPRi | HPRi | HPRi | Ri | Ri | Ri | Ri | Ri* | |
19 FEMALE | WfRi | WfRi | WfRi | WfHP RiA | HPRi | HPRi x | ||||||||
20 FEMALE | Wf | Wf | WfRi | WfHPLRi PtEA | HPL RiPt | x |
* = immediately after removal of animals from restraining tube
Ri* = increased respiratory rate day 8 only.
Table 6 Individual Bodyweights - Dose Group 1
Mean Achieved Atmospheric Concentration (mg/l) | Animal Number and Sex | Bodyweight (g) on day | At death | Increment (g) during week | |||
0 | 7 | 14 | 1 | 2 | |||
5.06 | 1 Male | 289 | 313 | 348 | 24 | 35 | |
2 Male | 294 | 325 | 370 | 31 | 45 | ||
3 Male | 288 | - | - | 264 | - | - | |
4 Male | 291 | 328 | 374 | 37 | 46 | ||
5 Male | 285 | 314 | 360 | 29 | 46 | ||
6 Female | 239 | - | - | 227 | - | - | |
7 Female | 233 | - | - | 217 | - | - | |
8 Female | 246 | - | - | 224 | - | - | |
9 Female | 238 | - | - | 220 | - | - | |
10 Female | 251 | 260 | 282 | 9 | 22 |
Table 7 Individual Bodyweights - Dose Group 2
Mean Achieved Atmospheric Concentration (mg/l) | Animal Number and Sex | Bodyweight (g) on day | At death | Increment (g) during week | |||
0 | 7 | 14 | 1 | 2 | |||
2.57 | 11 Female | 222 | 229 | 237 | 7 | 8 | |
12 Female | 232 | - | - | 212 | - | - | |
13 Female | 218 | - | - | 200 | - | - | |
14 Female | 222 | 228 | 236 | 6 | 8 | ||
15 Female | 219 | - | - | 199 | - | - |
Table 8 Individual Bodyweights - Dose Group 3
Mean Achieved Atmospheric Concentration (mg/l) | Animal Number and Sex | Bodyweight (g) on day | At death | Increment (g) during week | |||
0 | 7 | 14 | 1 | 2 | |||
2.57 | 16 Female | 217 | 230 | 250 | 13 | 20 | |
17 Female | 237 | 253 | 268 | 16 | 15 | ||
18 Female | 214 | 237 | 269 | 23 | 32 | ||
19 Female | 237 | - | - | 215 | - | - | |
20 Female | 238 | - | - | 208 | - | - |
Individual Necropsy findings for Dose groups 1 - 3 are attached (Please see Attachment 1).
Applicant's summary and conclusion
- Interpretation of results:
- harmful
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute inhalation median lethal concentration (LC50) and 95% confidence limits of the test material ALKANE 2, in the female Sprague-Dawley strain rat, were calculated to be 1.71 (0.49 - 5.99) mg/l.
The LC50 value for the males was estimated to be greater than 5.06 mg/l. - Executive summary:
- 1. A study was performed to assess the acute
inhalation toxicity of the test material, as supplied, by exposing groups
of Sprague-Dawley strain rats (five males and/or five females) to various
concentrations of an aerosol atmosphere. The animals were exposed for four
hours using a nose only exposure system. The method is designed to satisfy
the U.S. Environmental Protection Agency (EPA) Health Effects Test
Guidelines; 40 CFR Part 798.1150 "Acute Inhalation Toxicity" and the
recommendations of the OECD Guidelines for Testing of Chemicals (1981) No
403 "Acute Inhalation Toxicity" referenced as Method B2 in Commission
Directive 92/69/EEC (which constitutes Annex V of Council Directive
67/548/EEC). 2. The mean achieved atmosphere concentrations were as
follows:
Atmosphere concentration Group Number Mean Achieved mg/l Standard Deviation Nominal mg/l 1 5.06 0.19 19.1 2 2.57 0.12 9.9 3 1.19 0.09 4.5 3. The characteristics of the achieved atmospheres were as follows:
Group Number Mean achieved Atmospheric Concentration (mg/l) Mean Mass Medium Aerodynamic Diameter (microM) Inspiable Fraction (% <4 microM) Geometric Standard Deviation (microM) 1 5.06 1.7 82.0 0.40 2 2.57 1.8 85.2 0.46 3 1.19 1.7 86.2 0.45 4. The mortality data were summarised as follows:
Group Number Mean achieved Atmospheric Concentration (mg/l) Deaths Male Female Total 1 5.06 1 / 5 4 / 5 5 / 10 2 2.57 * 3 / 5 3 / 5 3 1.19 * 2 / 5 2 / 5 * - males were not exposed
5. Clinical Observations: Common abnormalities noted during the study were wet fur, hunched posture, pilo-erection, increased respiratory rate and ptosis. Isolated incidents of lethargy, ataxia, decreased respiratory rate, pallor of the extremities and tiptoe gait were also noted. Surviving animals recovered to appear normal 8 or 10 days after exposure.
6. Bodyweight: Surviving animals showed normal bodyweight gain during the study.
7. Necropsy: Common abnormalities noted at necropsy in animals that died during the study were swollen and abnormally dark lungs, dark liver and reddening of the small intestine. Two animals showed dark or pale kidneys. No abnormalities were detected in surviving animals at necropsy.
8. The acute inhalation median lethal concentration (LC50) and 95% confidence limits of the test material Alkane 2, in the femal Sprague-Dawley strain rat, were calculated to be 1.71 (0,49 - 5.99) mg/l.
The LC50 value for the males was estimated to be greater than 5.06 mg/l.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.